<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290806</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-090358</org_study_id>
    <nct_id>NCT04290806</nct_id>
  </id_info>
  <brief_title>Registry Platform Gastric/Esophageal Cancer (SAPHIR)</brief_title>
  <acronym>SAPHIR</acronym>
  <official_title>Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry aims to collect and analyse information on the antineoplastic treatment of
      patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in
      palliative intention in daily routine practice in Germany.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAPHIR is a national, observational, prospective, longitudinal, multicenter cohort study
      (tumor registry platform) with the purpose to record information on the antineoplastic
      treatment of metastatic esophageal, gastric or gastroesophageal junction Cancer in Germany.
      The registry will follow patients for up to two years. It will identify common therapeutic
      sequences and changes in the treatment of the disease. At inclusion, data in patient
      characteristics, comorbidities, tumor characteristics and previous treatments are collected.
      During the course of observation data on all systemic treatments, radiotherapies, surgeries,
      and outcome are documented.

      Health-related quality of life (HRQoL) will be evaluated for up to two years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Course of treatment (treatment reality)</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of anamnestic data and therapy sequences</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>ESCC</arm_group_label>
    <description>250 patients with esophageal squamous cell carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GAC</arm_group_label>
    <description>250 patients with gastric adenocarcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEJAC</arm_group_label>
    <description>250 patients with gastroesophageal junction adenocarcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine care as per site standard</intervention_name>
    <description>Physician's choice according to patient's needs. Routine care as per site standard.</description>
    <arm_group_label>ESCC</arm_group_label>
    <arm_group_label>GAC</arm_group_label>
    <arm_group_label>GEJAC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with metastatic (stage IV) esophageal squamous cell carcinoma (ESCC),
        gastric adenocarcinoma (GAC) or gastroesophageal junction adenocarcinoma (GEJAC), requiring
        palliative systemic first-line therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven stage IV (metastatic) ESCC, GAC or GEJAC

          -  Planned palliative systemic first-line therapy

          -  Age &gt;= 18 years

          -  Signed informed consent (IC)

               -  Patients answering questionnaires: IC before first therapy cycle

               -  Patients not answering questionnaires: IC latest 4 weeks after start of first
                  therapy cycle

        Exclusion Criteria:

          -  No systemic therapy for ESCC, GAC or GEJAC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Tobias Dechow, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Ravensburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albrecht Kretzschmar, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Leipzig</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florian Lordick, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Leipzig</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvie Lorenzen, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>MÃ¼nchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Potthoff, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Freiburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anke Reinacher-Schick, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Bochum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrian Binninger</last_name>
    <phone>+49 761 152 42 - 0</phone>
    <email>info@iomedico.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multiple sites, Gemany</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>iOMEDICO</last_name>
      <phone>+49761152420</phone>
      <email>info@iomedico.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoplasms</keyword>
  <keyword>registry</keyword>
  <keyword>health services research</keyword>
  <keyword>epidemiology</keyword>
  <keyword>Germany</keyword>
  <keyword>palliative treatment</keyword>
  <keyword>palliative care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

